

## Isofol invites to a live-streamed R&D Event on June 20 at 12.30 CEST

**GOTHENBURG, Sweden, June 14, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the company invites investors, analysts, and media to a live-streamed R&D Event with a subsequent question and answer session on June 20 at 12:30 CEST.**

Isofol will shortly present top-line results from the multi-center, global Phase III AGENT study investigating arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab in advanced, metastatic colorectal cancer (mCRC). The purpose of the event is to provide investors, analysts, and media with a better understanding of the current treatment landscape; medical need for colorectal cancer patients; clinical, regulatory and market access demands; and an update on the AGENT study. Speaking at the R&D Event will be Isofol's CEO Ulf Jungnelius MD, CMO/CSO Roger Tell MD, and Professor Sebastian Stintzing MD, Charité Universitätsmedizin, Division of Hematology, Oncology and Tumor Immunology. The event will be held in English.

### **Agenda for the R&D Event**

- The AGENT study – its design, patient population, endpoints, and an update including the current status of the study and upcoming topline results
- The medical need for colorectal cancer patients
- The current colorectal cancer treatment landscape and the clinical use of current treatments
- Clinical, regulatory, and market access demands for introducing new treatments for colorectal cancer
- Q&A-session

The event will be livestreamed and can be followed via a link that will be published on Isofol's webpage shortly

Questions can be asked prior to the event by sending an email to [info@isofolmedical.com](mailto:info@isofolmedical.com) or during the webcast via a chat function. The webcast will also be available on demand on Isofol's corporate website after the event.

### **Date and time**

June 20, 2022, from 12:30-14:00 p.m. CEST

### **Webcast link**

A link to the webcast will be published on Isofol's webpage shortly.

**For further information, please contact**

**Isofol Medical AB (publ)**

Ulf Jungnelius, M.D., Chief Executive Officer

E-mail: [jungnelius@isofolmedical.com](mailto:jungnelius@isofolmedical.com)

Phone: +46 (0) 709 16 89 55

*The information was submitted for publication, through the agency of the contact person set out above, at 10:00 CET on June 14, 2022.*

**About Isofol Medical AB (publ)**

Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck & Cie, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

[www.isofolmedical.com](http://www.isofolmedical.com)